View in EDS

Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.

Saved in:

Bibliographic Details
Title:	Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
Authors:	Tomida, Ryotaro¹ tomida.r@tokushima-u.ac.jp, Takahashi, Masayuki¹, Matsushita, Yuto², Kojima, Takahiro³, Yamana, Kazutoshi⁴, Kandori, Shuya⁵, Bando, Yukari⁶, Nishiyama, Naotaka⁷, Yamashita, Shimpei⁸, Taniguchi, Hisanori⁹, Monji, Keisuke¹⁰, Ishiyama, Ryo¹¹, Tatarano, Shuichi¹², Masui, Kimihiko¹³, Matsuda, Ayumu¹⁴, Kaneko, Tomoyuki¹⁵, Motoshima, Takanobu¹⁶, Shiraishi, Yusuke¹⁷, Kira, Satoru¹⁸, Murashima, Takaya¹⁹
Source:	Clinical Genitourinary Cancer. Jun2024, Vol. 22 Issue 3, pN.PAG-N.PAG. 1p.
Database:	Academic Search Ultimate

Description
ISSN:	15587673
DOI:	10.1016/j.clgc.2024.102094